

Roundtable 3: Considerations for Drug Development Programs in Rare Diseases

- * **Moderator: *Anne Pariser, FDA***
- * **Panelists: *John van den Anker, CNMC; Cristina Csimma, CEO, Cydan Development Inc.; Debra Miller, CureDuchenne; Peter Mueller, Vertex; John Porter, NINDS; Adriana Tremoulet, Kawasaki Disease Research Center, University of California San Diego***